Erste Group Bank Issues Negative Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Stock analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $6.34 per share for the year, down from their previous forecast of $6.96. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.51 per share.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Several other equities analysts also recently weighed in on BMY. Cantor Fitzgerald cut their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Roth Capital started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective for the company. TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. Finally, Piper Sandler cut their price objective on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $65.50.

Bristol Myers Squibb Trading Up 0.1%

Bristol Myers Squibb stock opened at $61.56 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a market capitalization of $125.75 billion, a price-to-earnings ratio of 9.44, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The stock has a 50-day moving average price of $63.20 and a 200 day moving average price of $59.79.

Institutional Investors Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC raised its stake in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the period. Callan Family Office LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $3,575,000. BlackRock Inc. grew its stake in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. Envestnet Asset Management Inc. grew its stake in Bristol Myers Squibb by 17.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock valued at $123,465,000 after acquiring an additional 317,360 shares during the period. Finally, Saudi Central Bank grew its stake in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after acquiring an additional 67,780 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.